Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3′ genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates

Vaccine

Volumn 25, Issue 34, 2007, Pages 6409-6422

  Nolan, Sheila M ^a   Skiadopoulos, Mario H ^a   Bradley, Konrad ^a   Kim, Olivia S ^a   Bier, Stacia ^a   Amaro Carambot, Emerito ^a   Surman, Sonja R ^a   Davis, Stephanie ^a   St Claire, Marisa ^a   Elkins, Randy ^a   Collins, Peter L ^a   Murphy, Brian R ^a   Schaap Nutt, Anne ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Human parainfluenza virus; Live attenuated vaccine candidates; Non human primate study

Indexed keywords

AMINO ACID; DNA DIRECTED DNA POLYMERASE ALPHA; INFLUENZA VACCINE; LIVE VACCINE; NUCLEOTIDE; PARAINFLUENZA VACCINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CERCOPITHECIDAE; GENE MUTATION; GENETIC STABILITY; IMMUNOGENICITY; LOWER RESPIRATORY TRACT; NONHUMAN; NUCLEOTIDE SEQUENCE; PARAINFLUENZA VIRUS 1; PARAMYXOVIRUS; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; TEMPERATURE SENSITIVE MUTANT; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; CELL LINE; CRICETINAE; HUMANS; MACACA MULATTA; MESOCRICETUS; MUTATION; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 2, HUMAN; PROMOTER REGIONS (GENETICS); RESPIRATORY SYSTEM; TEMPERATURE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 34547117389     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.028     Document Type: Article

References (51)

1. Knott A.M., Long C.E., and Hall C.B. Parainfluenza viral infections in pediatric outpatients: seasonal patterns and clinical characteristics. Pediatr Infect Dis J 13 4 (1994) 269-273
2. Korppi M., Halonen P., Kleemola M., and Launiala K. The role of parainfluenza viruses in inspiratory difficulties in children. Acta Paediatr Scand 77 1 (1988) 105-111
3. Monto A.S. The Tecumseh study of respiratory illness. V. Patterns of infection with the parainfluenzaviruses. Am J Epidemiol 97 5 (1973) 338-348
4. Glezen P., and Denny F.W. Epidemiology of acute lower respiratory disease in children. N Engl J Med 288 10 (1973) 498-505
5. Counihan M.E., Shay D.K., Holman R.C., Lowther S.A., and Anderson L.J. Human parainfluenza virus-associated hospitalizations among children less than 5 years of age in the United States. Pediatr Infect Dis J 20 7 (2001) 646-653
6. Reed G., Jewett P.H., Thompson J., Tollefson S., and Wright P.F. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J Infect Dis 175 4 (1997) 807-813
7. Henderson F.W., Collier A.M., Sanyal M.A., Watkins J.M., Fairclough D.L., Clyde Jr. W.A., et al. A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion. N Engl J Med 306 23 (1982) 1377-1383
8. Murphy B.R. Current approaches to the development of vaccines effective against parainfluenza viruses. Bull World Health Organ 66 3 (1988) 391-397
9. McAuliffe J.M., Surman S.R., Newman J.T., Riggs J.M., Collins P.L., Murphy B.R., et al. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J Virol 78 4 (2004) 2029-2036
10. Karron R.A., Belshe R.B., Wright P.F., Thumar B., Burns B., Newman F., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 22 5 (2003) 394-405
11. Karron R.A., Makhene M., Gay K., Wilson M.H., Clements M.L., and Murphy B.R. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in 2- to 6-month-old infants. Pediatr Infect Dis J 15 8 (1996) 650-654
12. Skiadopoulos M.H., Schmidt A.C., Riggs J.M., Surman S.R., Elkins W.R., St. Claire M., et al. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic. J Virol 77 2 (2003) 1141-1148
13. Skiadopoulos M.H., Surman S.R., St Claire M., Elkins W.R., Collins P.L., and Murphy B.R. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. Virology 260 1 (1999) 125-135
14. Bartlett E.J., Amaro-Carambot E., Surman S.R., Newman J.T., Collins P.L., Murphy B.R., et al. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 23 38 (2005) 4631-4646
15. Bartlett E.J., Amaro-Carambot E., Surman S.R., Collins P.L., Murphy B.R., and Skiadopoulos M.H. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates. Vaccine 24 14 (2006) 2674-2684
16. Nolan S.M., Surman S., Amaro-Carambot E., Collins P.L., Murphy B.R., and Skiadopoulos M.H. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine 39 23 (2005) 4765-4774
17. Murphy B.R. Mucosal immunity to viruses. In: Ogra P.L., Mestecky J., Lamm M.E., Strober W., McGhee J.R., and Bienstock J. (Eds). Mucosal immunology. 2nd ed. (1999), Academic Press, Inc. 695-707
18. Mossad S.B. Demystifying FluMist, a new intranasal, live influenza vaccine. Cleve Clin J Med 70 9 (2003) 801-806
19. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 191 7 (2005) 1093-1104
20. Belshe R.B., Newman F.K., Tsai T.F., Karron R.A., Reisinger K., Roberton D., et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 189 3 (2004) 462-470
21. Karron R.A., Wright P.F., Newman F.K., Makhene M., Thompson J., Samorodin R., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 172 6 (1995) 1445-1450
22. Skiadopoulos M.H., Vogel L., Riggs J.M., Surman S.R., Collins P.L., and Murphy B.R. The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations. J Virol 77 1 (2003) 270-279
23. Karron R.A., and Collins P.L. Parainfluenza viruses. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 5th ed. (2007), Lippincott Williams & Wilkins, Philadelphia 1497-1526 [Chapter 42]
24. Ogino T., Kobayashi M., Iwama M., and Mizumoto K. Sendai virus RNA-dependent RNA polymerase L protein catalyzes cap methylation of virus-specific mRNA. J Biol Chem 280 6 (2005) 4429-4435
25. Kolakofsky D., Le Mercier P., Iseni F., and Garcin D. Viral RNA polymerase scanning and the gymnastics of Sendai virus RNA synthesis. Virology 318 2 (2004) 463-473
26. Smallwood S., Easson C.D., Feller J.A., Horikami S.M., and Moyer S.A. Mutations in conserved domain II of the large (L) subunit of the Sendai virus RNA polymerase abolish RNA synthesis. Virology 262 (1999) 375-383
27. Smallwood S., Cevik B., and Moyer S.A. Intragenic complementation and oligomerization of the L subunit of the Sendai virus RNA polymerase. Virology 304 (2002) 235-245
28. Smallwood S., Hovel T., Neubert W.J., and Moyer S.A. Different substitutions at conserved amino acids in domains II and III in the Sendai L RNA polymerase protein inactivate viral RNA synthesis. Virology 304 (2002) 135-145
29. Andrejeva J., Childs K.S., Young D.F., Carlos T.S., Stock N., Goodbourn S., et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci USA 101 49 (2004) 17264-17269
30. He B., Paterson R.G., Stock N., Durbin J.E., Durbin R.K., Goodbourn S., et al. Recovery of paramyxovirus simian virus 5 with a V protein lacking the conserved cysteine-rich domain: the multifunctional V protein blocks both interferon-beta induction and interferon signaling. Virology 303 1 (2002) 15-32
31. Horvath C.M. Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein. Eur J Biochem 271 (2004) 4621-4628
32. Poole E., He B., Lamb R.A., Randall R.E., and Goodbourn S. The V proteins of Simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology 303 1 (2002) 33-46
33. Young D.F., Didcock L., Goodbourn S., and Randall R.E. Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response. Virology 269 2 (2000) 383-390
34. Tapparel C., Maurice D., and Roux L. The activity of Sendai virus genomic and antigenomic promoters requires a second element past the leader template regions: a motif (GNNNNN)3 is essential for replication. J Virol 72 4 (1998) 3117-3128
35. Juhasz K., Murphy B.R., and Collins P.L. The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination. J Virol 73 6 (1999) 5176-5180
36. Juhasz K., Whitehead S.S., Boulanger C.A., Firestone C.Y., Collins P.L., and Murphy B.R. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 17 11-12 (1999) 1416-1424
37. Whitehead S.S., Firestone C.Y., Karron R.A., Crowe Jr. J.E., Elkins W.R., Collins P.L., et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 73 2 (1999) 871-877
38. Skiadopoulos M.H., Durbin A.P., Tatem J.M., Wu S.L., Paschalis M., Tao T., et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol 72 3 (1998) 1762-1768
39. Skiadopoulos M.H., Surman S., Tatem J.M., Paschalis M., Wu S.L., Udem S.A., et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 73 2 (1999) 1374-1381
40. Feller J.A., Smallwood S., Skiadopoulos M.H., Murphy B.R., and Moyer S.A. Comparison of identical temperature-sensitive mutations in the L polymerase proteins of sendai and parainfluenza 3 viruses. Virology 276 1 (2000) 190-201
41. Buchholz U.J., Finke S., and Conzelmann K.K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73 1 (1999) 251-259
42. Hall S.L., Stokes A., Tierney E.L., London W.T., Belshe R.B., Newman F.C., et al. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res 22 3 (1992) 173-184
43. Newman J.T., Riggs J.M., Surman S.R., McAuliffe J.M., Mulaikal T.A., Collins P.L., et al. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. J Virol 78 4 (2004) 2017-2028
44. Newman J.T., Surman S.R., Riggs J.M., Hansen C.T., Collins P.L., Murphy B.R., et al. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 24 1 (2002) 77-92
45. Skiadopoulos M.H., Tao T., Surman S.R., Collins P.L., and Murphy B.R. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine 18 5-6 (1999) 503-510
46. van Wyke Coelingh K.L., Winter C.C., Tierney E.L., Hall S.L., London W.T., Kim H.W., et al. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus. J Virol 64 8 (1990) 3833-3843
47. Itoh M., Isegawa Y., Hotta H., and Homma M. Isolation of an avirulent mutant of Sendai virus with two amino acid mutations from a highly virulent field strain through adaptation to LLC-MK2 cells. J Gen Virol 78 Pt 12 (1997) 3207-3215
48. Blaney Jr. J.E., Johnson D.H., Firestone C.Y., Hanson C.T., Murphy B.R., and Whitehead S.S. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice. J Virol 75 20 (2001) 9731-9740
49. Shimizu K., Mullinix M.G., Chanock R.M., and Murphy B.R. Temperature-sensitive mutants of influenza A/Udorn/72 (H3N2) virus. II. Genetic analysis and demonstration of intrasegmental complementation. Virology 117 1 (1982) 45-61
50. Murphy D.G., Dimock K., and Kang C.Y. Numerous transitions in human parainfluenza virus 3 RNA recovered from persistently infected cells. Virology 181 2 (1991) 760-763
51. Bass B.L. RNA editing and hypermutation by adenosine deamination. Trends Biochem Sci 22 5 (1997) 157-162